🇺🇸 FDA
Patent

US 11873495

Compounds and methods for reducing LRRK2 expression

granted A61KA61K31/7115A61K31/712

Quick answer

US patent 11873495 (Compounds and methods for reducing LRRK2 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K31/7115, A61K31/712, A61K31/7125, A61K47/02